The centromere and promoter factor Cpf1 binds centromere DNA element I found in all centromere DNAs from the yeast Saccharomyces cerevisiae. 
INTRODUCTION
The centromere and promoter factor 1 (Cpfl) from budding yeast (1, 2, 3) belongs to the family of basic helix-loop-helix (bHLH) proteins encompassing the mammalian transcription factor Myc (4), Max (5) and MyoD (4), the immunoglobulin enhancer binding proteins E12 and E47 (4) and the transcriptional activator Pho4 (6) . Members of the bHLH family are involved in diverse processes like transcriptional regulation, oncogenesis and/or cell type determination, differentiation and in centromere function. The bHLH proteins can form homo-and/or heterodimers via two amphipathic a-helices connected by a loop (HLH region) (7) . This dimerization is essential for sequence-specific DNA binding which is mediated by the basic region of these proteins. Part of the DNA sequence recognized by all bHLH proteins fits the consensus sequence CANNTG with a subclass recognizing C-AGCTG (class A) and the other subclass recognizing CACGTG (class B) (8) .
The Cpfl protein binds centromere DNA element I (CDEI) present in all Saccharomyces cerevisiae centromere DNAs (CEN DNAs). The CDEI sequences from 15 of the 16 yeast CEN DNAs described fit the general consensus sequence RTCACRTG (position 1 to 8, Tab. 1), where R is an A or G (reviewed in 9, Fleig, Beinhauer and Hegemann, unpubl.), although more than this minimal CDEI sequence is needed for high fidelity centromere function (10) . Cpfl is essential for high fidelity mitotic and meiotic chromosome segregation. Disruption of CPF 1 leads to a 10 to 50 fold increase in mitotic chromosome loss rate and to an increase in meiosis I chromosome nondisj unction (reviewed in 9). Additionally Cpfl binds to DNA sequences very similar to CDEI in the promoter regions of various genes including those involved in methionine biosynthesis (11, 3, 12, 13) where it seems to be involved in transcriptional regulation. Disruption of CPF 1 results in methionine auxotrophy (1, 2, 3) . Although chromatin analysis has shown that Cpfl has target sequences in the promoter region of several Met genes (14, 15, 16, 17) , no correlation between Cpfl binding to these DNA sequences and methionine prototrophy could be detected (18, 3) . Attempts to create separation of function mutants (methionine auxotrophy or reduced centromere function) of CPF 1 have only been partly successful (19, 20, 21) .
The Cpfl binding site CDEI is one of the three conserved yeast centromere DNA elements, which altogether are about 120 bps in size and are necessary and sufficient for complete mitotic and meiotic centromere function (22) . In vivo footprint and chromatin studies strongly indicate binding of Cpfl to CDEI in yeast centromeres (3, 23) . Deletion of CPF 1 results in changes in the centromere chromatin at the location of CDEI. In vivo footprint experiments in CPF1 deletion strains have shown that previously protected G nucleotides in CDEI become accessible to dimethylsulfate (3) .
T o whom correspondence should be addressed Mutational analysis of CDEI from chromosome VI (CEN6) had indicated that base pairs (bp) of the palindromic part of CDEI, CACRTG (position 3 to 8, Fig.3B ), are most important for proper mitotic chromosome transmission. Furthermore the two conserved bps at position 1 and 2 and the two nonconserved bps to the right of CDEI at position 9 and 10 also play a role in mitotic CEN function albeit to a much lesser extent (10) . Double point mutants in CDEI and CDEIII are synergistic and thus not purely additive effects; the double mutants show a much higher mitotic chromosome loss rate than the sum of the individual chromosome loss rates of the single mutants. Thus the CDEI/Cpf 1 complex might interact with other DNA/protein complexes located at CDEH and/or CDEHI (10) . One possibility to facilitate interactions between the CDEI/Cpfl complex and other centromeric DNA/protein complexes is protein induced DNA bending. Recently it could be shown that Cpfl bends CDEI with a bend angle of about 70° (24) . Similar findings have been made for other HLH proteins (summerized in 25) .
The 16 different CDEI elements have the general consensus sequence RTCACRTG and can be subdivided into two subgroups. Eight of these 16 CDEI elements have within their binding site the perfect palindromic hexanucleotide CACGTG, while seven other elements carry the sequence CACATG. The exception is CEN2-CDEI, which has the motif CATGAG (summerized in: 9; Fleig, Beinhauer and Hegemann, unpubl.). Thus the various CDEI sequences are very closely related, but not identical. In yeast other HLH proteins have been described which recognize sequences similar to CDEI (26, 27) . For Pho4 a clear discrimination between Pho4 and Cpfl binding sites has been found. Both proteins bind the core sequence CACGTG, but while binding of Pho4 in vitro is inhibited by the presence of a T:A base pair immediately 5' to the CACGTG motif, binding by Cpfl is not (27) . All 16 CDEI elements carry this T:A base pair at position 2 thus inhibiting binding by Pho4 protein.
As the different CDEI sites are not identical, how does the Cpfl protein achieve its affinity binding to these sites in vivo! Most likely specificity of Cpfl to its target element is predominantly determined by the sequence specific recognition of the CDEI element. Additionally the specific sequence environment around CDEI sequences and/or protein-protein interactions may help to 'anchor' Cpfl to its binding site. Single base pair changes in CDEI negatively influence the fidelity of mitotic chromosome segregation (10) . This might be due to a reduced affinity of the Cpfl protein to the modified binding site and/or due to distorsions in the CDEI/Cpfl complex and other proteins interacting with it. Thus it is possible that the DNA binding specificity of the Cpfl protein is influenced by cooperative interactions with other centromeric proteins. One could postulate that mutations near the binding site of Cpfl that decrease centromere function, but do not affect its binding in vitro may be indicative of such an in vivo protein-protein cooperative interaction. A prerequisite for such an analysis is a thorough understanding of the CDEI binding site and the functional consequences of mutations in or around CDEI.
In an attempt to analyze the binding requirements of Cpfl to CDEI in detail, an in vitro analysis of the relative binding affinities of Cpfl to point mutated CDEI elements from CEN6 was untertaken and compared with the in vivo centromere activity of these mutants. We found that Cpfl binding in vitro as well as full in vivo centromere function requires a 10 bp recognition sequence including the 8 bp long CDEI. CDEI elements from different chromosomes carrying different DNA sequences are recognized by Cpfl in vitro with the same affinity and as part of the respective centromere show the same in vivo activity. CDEI mutants located in the hexanucleotide CACGTG show strongly reduced relative affinities to Cpfl protein. This corresponds to the in vivo analysis of these mutants, which in general also exhibit strongly increased chromosome loss rates when analyzed in vivo in the context of a centromere (10) . Interestingly the degree of chromosome loss rate attributable to the various CDEI mutants does in general not parallel the order of their affinity for Cpfl protein. Symmetrical mutations in either half site of the palindromic sequence CACGTG affect binding affinity to a different extent. In vivo the observed asymmetry is much stronger. Interestingly several CDEI mutants located outside the palindrome showed an increase in chromosome loss but had better than wild type binding in vitro. These data indicate that the Cpfl interaction with CDEI is differently in vitro and in vivo. We would like to suggest that in the in vivo situation Cpfl protein binding to CDEI may interact with other centromeric DNA/protein complexes to achieve optimal binding and function. Media, transformation, enzymes and oligonucleotides The different nonselective (YPD and SD complete) and selective (SD noncomplete) media for yeast and the media (YT and M9) for bacteria were as described previously (45) . Yeast transformations were done using the LiOAc method according to Ito et al. (1983) . The enzymes were purchased from various companies and used according to the suppliers. Oligonucleotides were synthesized with an Applied Biosystems DNA synthesizer 380B using the phosphoramidite chemistry.
MATERIALS AND METHODS

Strains
Mutagenesis
All mutations created in this study were introduced into the CEN6 DNA with PCR. 
Determination of chromosome fragment (CF) loss rate
The mitotic centromere activity of the CDEI mutants were measured on an artifical chromosome fragment using the cycloheximide R/S system as described previously (30) . The fragmentation vectors carrying the various CDEI mutations were linearized with Notl and transformed into the yeast strain YJH6.
Transformants carrying a CF were identified by OF AGE analysis. From one transformant 50 to 150 cells were plated onto nonselective SD+6 plates and allowed to grow to colonies containing about 5X10 4 cells. Ten colonies of equal size were picked and resuspended in sterile water. Then 98 % of the cells were plated onto two SD+6 plates containing cycloheximide (Sigma, concentration 10/ig/ml), the remaining 2% onto five SD+6 plates. The number of colonies grown on SD+6 plates and on SD+6+cycloheximide plates were counted and the rate of loss per mitotic cell division was obtained by the method of the median as described by Hegemann et al. (1988) .
Preparation of crude yeast protein extracts ABYS60 was grown in 100ml of YPD to an optical density at 600nm of 1 to 1.5. Cells were harvested, washed once with 20 ml of buffer A100 (20mM N-2-hydroxyethylpiperazine-N'-2-ethansulfonic acid (HEPES) NaOH (pH 7.5), 5mM MgCl 2 , lOmM /3-mercaptoethanol, lmM phenylmethylsufonyl fluoride, 0.2mM EDTA, 15% glycerol, lOOmM NaCl) and resuspended in 2 ml of buffer A100. Cells were lysed by adding an equal volume of nitric acid treated glass beads (0.45-0.55 mm of diameter, Braun Melsungen) and vigorous vortexing for 10x30sec, followed by lmin incubation on ice (less than 10 % of intact cells was optimal). The cell lysate was centrifuged for lOmin at 120Xg (4°C). Five molar NaCl was added to the turbid supernatant to a final concentration of 1.5M to dissoziate DNA/protein complexes. This mixture was centrifuged for 20min at 12.000Xg (4°C). The resulting supernatant was aliquoted and stored for further use at -20°C.
Band shift assays /. Preparation of probe and competitor DNA. Wild type and mutated CEN6-CDEI sequences were isolated from the corresponding pKE-plasmids (this study, 45, 10) by PCR with two oligonucleotides, whose sequences are complementary to sequences left (5'CCTGTATAATATAAGCTTGAAGA-CTATA3', oligo 102) and right (5'TTTATATATCTA-GATTAAAAAATTTAAATTA3', oligo 103) of CEN6-CDEI (Mrtdin and Xbal restriction sites are boldface). The PCR products (91 bp length) were cleaved HindlWXbal and the 65 bp fragments were cloned into pBluescript II SK + (Stratagene). All CDEI mutations were verified by sequencing.
To prepare the DNA probe the 65bp wt CEN6-CDEI fragment was isolated from the corresponding pBluescript vector. About 80ng (2pmol) of the fragment was 3' end labelled at the Xbal site with 10 /iCi of [a-
32 P]dCTP (3000 Ci/mmol, Amersham). The labelling reaction was passed through a 1.5 ml Sephadex G-100 column equillibrated with TE buffer to remove unincorporated radioactive nucleotides. The resulting probe had a concentration of 5 fmol//il.
Ten fig of the pBluescript vectors carrying the various CDEI mutations were digested with ffindlll and Xbal in 50 /il A100 buffer (= 4 ng specific competitor//tl (= 100 fmol//il) and used without further purification. //. Competition band shift assay. DNA/protein binding reactions were performed as decribed (29): 5 fmol radiolabelled wt CEN6-CDEI probe were mixed with 0.5 fig of calf thymus DNA as unspecific competitior DNA and the indicated amount of specific competitor DNA and filled up to a volume of 17/il with buffer A100. After mixing 1/il of crude yeast protein extract was added, incubated at room temperature for 5min, then 2/xl of gelloading buffer (0.25% bromophenol blue; 0.25% xylene cyanol, 50% glycerol in TBE buffer [90 mM Tris,90 mM boric acid, 0.1 mM EDTA, pH8.8]) was added. The DNA/protein complexes were separated from unbound DNA by electrophoresis through 5% native polyacrylamide gels, dried and exposed at -70°C for 12 hrs.
Determination of relative equilibrium affinities
The bands representing the CDEI/Cpf 1 complexes were cut out of the gel and quantified by Cerenkov counting. For determination of the relative affinities the signal intensity of the band obtained in the presence of a 160 fold molar excess of specific competitor was used. This amount of specific competitor yielded differences between different competitor CDEI mutants which were easy to detect and quantify. The relative equilibrium affinities were calculated as follows: the intensity of the band representing the CDEI/Cpf 1 complex obtained without competitor DNA was set as 100 %. Competition with a 160 fold molar excess of wt CEN6-CDEI DNA gave a retarded band with a reduced radioactive signal compared to the intensity of the band without competitor. Competition with wt CEN6-CDEI was repeated 39 times and on average the band intensities were reduced to 4.9 ± 0.5 % relative to the intensity without competitor. The bands representing the CDEI/Cpfl complex obtained in the presence of CDEI mutant competitor DNAs were quantified and the data divided by 4.9 to obtain the factor, by which this CDEI mutant was able to bind Cpfl protein better or worse than wt CDEI. The standard deviation was calculated on the basis of 2 to 4 independent experiments.
RESULTS
The minimal length of CDEI necessary for full Cpfl binding in vitro and mitotic centromere function in vivo is 10 bps
The Cpfl binding site was originally defined by comparing CDEI sequences from different centromeres and establishing a 8 bp long CDEI consensus sequence. Point mutations introduced into this CDEI sequence were analyzed for their in vivo meiotic and mitotic centromere function (reviewed in 9). The data indicated that in addition to the 8 bp CDEI element base pairs at position 9 and 10 to the right of CDEI (formerly defined as belonging to CDEII) (see Fig. 3 ) were also relevant for complete centromere function (10) . DNasel protection studies had indicated that binding of Cpfl to CDEI protects between 12 and 25 bps (11, 28, 29) . In order to rigorously test whether a 10 bp long CDEI element (position 1 to 10, Fig. 1 ) was sufficient for in vitro binding of Cpfl protein and for complete mitotic centromere function, the 6 bps left and/or right of the 10 bp long CEN6-CDEI sequence were mutated. As CDEIs are normally surrounded by an AT content of more than 80 % (22) GC stretches were brought in (mutations CDEI(M1), CDEI(M2) and CDEI(M3), Fig. 1A and Tab. 1). In order to determine the ability of a mutated CDEI sequence to be recognized by Cpfl protein in vitro relative equilibrium affinities were determined with the help of band shift assays (see later, Fig. 2 ). As preliminary experiments had shown that certain CDEI mutations did not give rise to a retarded signal because they were not able to form a complex with Cpfl (24), an indirect assay was established, in which the mutated CDEI sequences were used as competitiors. DNA fragments carrying individual CDEI mutations were used in binding reactions with a radioactively labelled 65 bp long probe containing wt CDEI from CEN6 and crude yeast protein extracts. Separation of the binding reaction on nondenaturing polyacrylamide gels yielded a distinct band representing the CDEI/Cpfl DNA/protein complex (Fig. 2) . Deletion of the CPF1 gene results in loss of this signal (24) . Unlabeled competitor DNA was added to the binding reaction in a 10, 20, 40, 80 or 160 fold molar excess relative to the amount of the labeled probe. The analysis of CDEI(M1), CDEI(M2) and CDEI(M3) for in vitro binding affinity to Cpfl protein revealed that they were able to bind to the protein with the same affinity as wildtype CDEI sequences do (Fig. IB) . Addition of a forty fold molar excess of the specific competitor led in each case to a complete loss of the retarded signal.
Mutants CDEI(Ml), CDEI(M2) and CDEI(M3) were also analyzed for their mitotic centromere activity by replacing (Fig. IB) , thus the loss rates were only increased by a factor of 1.15 to 1.45. This indicates that the 10 bp long CEN6-CDEI sequence is sufficient for wild-type like Cpfl binding in vitro and complete mitotic CEN function. The AT rich sequences normally found for the sequences surrounding CDEI do not appear to be required for Cpfl binding or for mitotic centromere activity as it can be replaced by GC stretches without reducing in vivo function (CDEI(M3) in Fig. 1 ).
Relative binding affinities of Cpfl protein to CDEI mutations within the CACGTG motif do not correlate to their in vivo activity Knowing the minimal length of the CDEI sequence required for high fidelity centromere function, we asked whether the ability of Cpfl protein to bind a mutated CDEI sequence might relate to the ability of that mutant to confer in vivo CEN activity. The relevance of the Cpfl binding site CDEI for mitotic CEN function has been studied in a site directed mutational analysis using CDEI from CEN6 (CEN6-CDEI) (10) . We wanted to know whether the reduced in vivo CEN function of a CDEI mutant is reflected by a correponding reduction in affinity of Cpfl to this mutation. A set of 23 single point mutations within CEN6-CDEI which all adversely affect mitotic centromere function was chosen (10) . The binding ability of CDEI mutations to Cpfl protein was quantified by band shift assays. Examples for such competition assays are presented in Fig. 2A to D. In Fig.2A competition with the wt CEN6-CDEI sequence is presented, while to compete out wt CDEI compared to the control competition with wt CDEI (compare Fig. 2B and 2A) . The relative affinity of Cpfl protein is about 10 fold lower for CDEI(6-A) than for wt CDEI (; see Materials and Methods for details of calculation). Likewise mutation CDEI(8-T) has a 15 fold lower relative affinity for Cpfl than wt CDEI (compare Fig. 2C with 2A) . Unexpectedly mutation CDEI(9-A) can compete out wt CDEI better than wt CDEI itself (compare Fig. 2D with 2A) .
A compilation of the data obtained for all 23 CDEI mutations analyzed is presented in Fig. 3A . The relative affinities are shown as x-fold lower or higher binding affinity compared to wt CDEI binding by Cpfl (Fig. 3A) . The results clearly demonstrate that base pair changes in the palindrome CACGTG of CDEI exert the strongest effects on Cpfl binding. All changes within the C-ACGTG sequence result in a significantly lower binding affinity ranging from a 6.1 fold decrease for CDEI(6-C) to a 14.8 fold decrease for CDEI(8-T). The biggest reductions in binding affinity can be seen for CDEI sequences that have base pair changes at the first C:G bp (position 3) and the last G:C bp (position 8) of the palindrome: mutation CDEI(3-G) exhibited an 14.6 fold and mutation CDEI(8-T) an 14.8 fold decrease in binding affinity.
Cpfl protein recognizes CDEI sequences asymmetrically in vitro
Interestingly symmetrical mutations disrupting either half site of the palindrome affect Cpfl binding capacity to a different extent. Mutations disrupting the left half site of the palindrome affect Cpfl binding stronger than the corresponding mutations in the right half site. For example, Cpfl protein has a lower binding affinity to mutation CDEI(5-A) (10.6 fold reduced) compared to the symmetrical mutation CDEI(6-T) (8.7 fold reduction). This half site asymmetry is found in all but one of the symmetrical mutations analyzed.
A comparison of the in vitro binding affinities of the CDEI mutations with their in vivo centromere activity (10) reveals that the half site asymmetry is found in both assays albeit to a different extent (compare Fig. 3A with 3B) . The difference between two symmetrical mutants disrupting the left or the right halves of the palindrome analyzed in vivo has been shown to be in the range of two-to seven-fold, while symmetrical mutations in vitro differ by a factor of 1.5 fold indicating that the asymmetrical behavior is much stronger in vivo. Another significant difference between the data obtained for the mutants in vivo and in vitro concerns the effects of the three possible mutations at a given position. For example the three possible changes at position CDEI(5-C) show a decreasing affinity for Cpfl in vitro in the order of (5-G), (5-A) and (5-T) (Fig. 3A) . In vivo the order of these mutants is different: mitotic chromosome loss rates found for these mutants increase from (5-T) to (5-G) and to (5-A) (Fig. 3B) . This is true for all positions within the palindromic core sequence C-ACGTG except position 4, where the mutations CDEI(4-G) and CDEI(4-C) follow the same sequence in vitro and in vivo (Fig.  3 ). An interesting mutation is CDEI(6-A), which when analyzed in vivo exhibits an almost wildtype-like chromosome loss rate, but when studied for Cpfl binding in vitro showed a 9.1 fold reduced binding affinity. Thus although this CDEI mutant works well in our vivo assay, its in vitro affinity for Cpfl protein is greatly reduced.
Mutations in base pairs flanking the CDEI palindrome CACGTG show a higher affinity to Cpfl protein than wildtype CDEI Surprisingly three point mutations showed a significantly better than wt binding although they reduce CEN function in vivo. The mutations CDEI(l-G), CDEI(9-A) and CDEI(IO-C) are able to compete out the labeled wt DNA fragment completely at a 20 fold molar excess. When wt CDEI is used for competition, a 40 fold molar excess is needed (compare Fig. 2D with 2A) . The three mutant CDEI sequences have an affinity to Cpfl, which is between 1.4 and 2.3 fold higher than wt CDEI has, but in vivo show a 1.2 to 2.3 fold increase in chromosome loss. Other base pair changes left and right of the CACGTG palindrome (positions 1, 2, 9 and 10 of CDEI) can lead to a moderate reduction in protein binding (Fig. 3A) .
The observed differences between the data obtained in vivo and in vitro and in particular the finding that some CDEI mutations outside of the palindromic CACGTG sequence show a stronger Cpfl binding than the wt CDEI sequence indicate that the Cpfl binding requirements in vivo are not completely A. In vitro binding capacity of CPF1 to CDEI point mutations. 
Enlarged palindromic CDEI sequences show high affinity binding to Cpfl in vitro but reduced CEN function in vivo
The CEN6-CDEI mutation CDEI(9-A) exhibited a 2.3 fold higher relative binding affinity to Cpfl protein than wt CDEI did. As this mutation extends the CDEI palindrome from CACGTG (6 bps) to ATCACGTGAT (10 bps), it was possible that other palindromic CDEI variants would also yield better than wildtype binding affinity to Cpfl and might even show a better than wt CEN function as was shown for such mutants in CDEIII (24) . Four different CDEI palindromic variants were analyzed for their relative binding affinities for Cpfl. Triple mutation CDEI(l-G,9-A,10-C) shows a 10 bp palindrome (CDEI position 1 to 10) (Fig. 4A ) and combines the three single point mutations, which in our assay had shown to bind Cpfl better than wt CDEI does (compare Fig. 3A and Fig. 4B ). Indeed the triple mutant has a 3.8 fold higher affinity for Cpfl protein than wt CDEI has (Fig. 4B) . The affinity for the triple mutant is higher in comparison to the affinities of the three single mutations (Fig.  3A) . Interestingly the mitotic chromosome loss rate of CDEI(l-G,9-A,10-C) is close to wildtype (5.9 x 10~4 compared to 4.7 X 10~4). In an attempt to possibly further improve Cpfl binding and/or CEN activity additional CDEI mutations were created. Based on the triple mutant DNA sequence the CDEI variant [CDEI(M4) was designed, which carries an additional bp change at position -1 (C:G to T:A) thus leading to a 12 bp palindrome. CDEI(M4) showed a relative affinity to Cpfl protein about 2 fold higher than wt CDEI, but when analyzed in vivo an 2.6 fold lower CEN activity (Fig. 4) . The additional bp change alone [CDEI(-l-T)] when analyzed showed wt-Cpfl binding affinity and a 1.7 fold increase in mitotic chromosome loss. To further elongate the palindrome, CDEI(M5) was designed which carries a 20 bp inverted repeat. This mutant showed a 2 fold increase in affinity to Cpfl protein and a 2.3 fold increase in chromosome loss (Fig. 4) . Thus palindromic sequences longer than 10 bp do not further optimize binding of Cpfl. This is also true for the double mutant CDEI(-1-T,9-A), which has a perfect 12 bp palindrome (Fig. 4) .
The five CEN6-CDEI mutations which have 10 bp or longer palindromic sequences plus the A:T base pair at position 9 exhibit better than wt binding to Cpfl protein in vitro. This is not the case for mutation CDEI(2-G) which also carries a 10 bp palindrome but no A:T base pair at position 9. This mutant shows reduced binding affinity in vitro and when analyzed in yeast a reduced CEN function in vivo (Fig. 4) . These data reinforce the relevance of the A:T base pair at position 9 of CDEI together with a palindromic structure for optimal Cpfl binding in vitro (see discussion for details). 
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B. 10 were relevant for CEN function (10) . We show that these 10 bp sequence is sufficient for in vitro Cpfl binding and in vivo CEN function (Fig. 1) , as GC stretches introduced left and right of this sequence show no adverse effect. Interestingly six of the seven naturally occuring CDEI elements with non perfect CACGTG palindrome carry an A:T bp at position 9 (CEN1, CEN2, CEN3, CEN11, CEN13, CEN16) (9) . Base pair changes in CEN6-CDEI yielding such non perfect palindromic sequences always led to a significant decrease in in vivo centromere activity and in vitro Cpfl binding. We therefore asked which affinities wild-type CDEI elements with nonperfect palindromes would have for Cpfl protein. We determined the relative equilibrium affinities for CEN2-CDEI (CAJGTG) and CEN3-CDEI (CACATG) and found that both elements bind Cpfl like CEN6-CDEI (Fig. 5) . CEN2-CDEI carries a T:A base pair at position 5 of CDEI and CEN3-CDEI carries an A:T base pair at position 6 of CDEI. The CEN2 equivalent mutation in CEN6 [CDEI(5-T)] gave a 12 fold decrease in binding affinity to Cpfl and when analyzed in vivo showed a 3.5 fold increase in mitotic loss rate. Wild-type CEN2 has a mitotic loss rate identical to CEN6 (31) . Similar data were obtained for CEN6-CDEI(6-A) and wild-type CEN3-CDEI (Fig. 5) . Both CEN2-CDEI and CEN3-CDEI carry the A:T base pair at position 9 and thus it appears that the presence of an A:T bp at this postion can compensate for single base pair changes in the CACGTG palindrome in vivo and in vitro.
DISCUSSION
The integral part of the target sequence recognized by all bHLH proteins is the CANNTG hexanucleotide; with a subset of proteins recognizing sequences with the core element CACGTG. In yeast the bHLH protein Cpfl, the centromere and promotor factor 1, binds as a homodimer to the centromere DNA element CDEI (1,2,3) and this complex is needed for high fidelity chromosome segregation in mitosis and meiosis. Here we present a comparative analysis of the requirements for in vitro complex formation and in vivo centromere activity of the CDEI/Cpf 1 DNA/protein complex from CEN6.
A mitotically fully functional CDEI element is 10 base pairs long
The data presented show that a 10 base pair CEN6-CDEI sequence comprised of the conserved 8 bp sequence ATCACGTG (pos. 1 to 8) plus additional 2 bps to the right at position 9 and 10 in conjunction with CDEII and CDEm is sufficient for complete mitotic centromere function. The required size of 10 bps is significantly shorter than previously indicated by in vitro DNasel footprint experiments, which had identified a 12 to 25 bp long region (11, 29, 28) . Data obtained with in vivo DMS footprints of CEN6-CDEI are in agreement with our in vivo data for the minimal CDEI element, as only the guanine nucleotides at positions 6 and 8 in the upper strand and positions 3, 5 and 9 in the lower strand were found to be protected against methylation (3, 32) . Our CDEI minimization experiment indicates that the ATrichness normally found left and right of CDEI (on average 75 % AT to the left and > 90 % AT to the right) are not necessary for Cpfl binding and activity (Fig. 1) . However, a role of these sequences in other processes such as meiotic CEN function cannot be excluded.
The in vitro mutant CDEI/Cpfl binding affinities do not parallel the in vivo centromere activity of these mutants The CDEI/Cpfl complex plays an important role in mitotic centromere function as a deletion of either CDEI sequence or Cpfl gene increases the mitotic loss rate 10 to 50 fold (summerized in 9). One might postulate that mutations in CDEI that decrease CEN activity show a reduction in their ability to be bound by Cpfl and furthermore that there is a correlation between CEN activity and binding affinity of Cpfl to CDEI sequences. Our analysis of the binding properties of 23 point mutated CDEI elements to the Cpfl protein strongly argues in favor of the first and against the second assumption.
Generally, the relative affinities of Cpfl protein to CDEI elements mutated in the central palindromic core sequence C-ACGTG (position 3 to 8) are strongly reduced similar to what has been described for the in vivo centromere activity of these mutants (Fig. 3) . Surprisingly however , a detailed comparison of the chromosome loss rates and binding data shows that the binding affinity of Cpfl to the point mutant CDEI elements does not correlate with the CEN activities of these CDEI variants. For example, mutation CDEI(8-T) has the strongest reduction in binding affinity to Cpfl protein of all mutations analyzed. And in an in vivo footprint analysis of this mutant significant changes in the pattern of protected and accessible G nucleotides within CDEI in comparison to wildtype CDEI could be observed (Hinz and Hegemann, unpubl. data). But when CDEI(8-T) was analyzed for its chromosome loss rate, its centromere activity was only moderately decreased and better than those of 12 other CDEI mutants (Fig. 3) . The relative order of the mutations to each other in the in vitro assay and in the in vivo assay differs. This strongly indicates that the CDEI DNA requirements for in vitro binding and for in vivo centromere function are different. Previously the opposite conclusion had been reported namely that in vitro binding and in vivo activity of CDEI point mutations parallel each other, but in these experiments only a subset of 5 CDEI mutations (from positions 7 and 8) and a truncated version of Cpfl protein had been used (2) . It is likely that the binding affinity of a truncated Cpfl protein to mutated CDEI sequences is different from that observed for full length protein. Indeed it was found that a shortened Cpfl protein produced in yeast or in E. coli bends its target DNA in a different direction compared to full length Cpfl (3, 34) . Likewise the full-length protoonco-protein c-Myc is unable to bind its target sequence, while a truncated form of cMyc, aa 342 -439, is able to bind (35) . Single amino acid exchanges within the DNA binding domain of certain DNAbinding proteins can induce altered DNA binding specificities (36, 37) . Finally, single amino acids changes within the basic region of Cpfl can lead to a different DNA binding specificity (8) .
The non-palindromic base pairs at positions 1,2,9 and 10 are less relevant for both Cpfl binding in vitro and CEN function. Interestingly three point mutations at these positions exhibit a binding affinity which is higher than the affinity of wt CDEI, while in vivo these mutants have moderately increased chromosome loss rates. These base pairs are probably needed to exclude binding of other bHLH proteins to the CDEI sites. For example, it has been shown that the T:A base pair at position 2 of CDEI inhibits binding of Pho4 protein to this site in vitro (27) .
The absence of a correlation between the level of in vivo activity and in vitro Cpfl binding found for most of the CDEI point mutations can be explained in at least three ways. First Cpfl binding to CDEI induces a DNA distorsion with the induced bend directed towards the major groove (24) . Thus the binding affinities of Cpfl to CDEI mutants and/or the corresponding in vivo centromere activity might be modulated by changes in the bending properties. But when the bending of various CDEI mutants when bound by Cpfl were analyzed no changes were observed (24) . Therefore binding of Cpfl to mutant CDEI DNA sequences does not appear to influence the bending pattern of this complex and thus cannot account for the discrepancy between in vitro and in vivo data. Second Cpfl binding in vivo may need cofactors which modulate the interactions in the CDEI/Cpfl complex and which are absent in our protein preparation. We find this possibility unlikely, as crude yeast protein extract was used in our experiments. In contrast to the CDEI/Cpfl complex, for CDEIII and its binding complex CPF3 a cofactor has been identified, although its nature is not known yet (38) . Third the CDEI/Cpfl complex may undergo interactions with other centromere components which in turn could modulate the CDEI/Cpfl interactions in vivo. There is indeed genetic evidence for such an interaction between different CDE DNA/protein complexes: double mutations in CDEI and CDEIII resulted in chromosome loss rates much higher than when the loss rates of the two single mutations were added (10) . Furthermore, in vivo footprints of a CDEIII point mutated CEN3 sequence revealed not only changes in the pattern of protected and enhanced G nucleotides in CDEIII but also changes in the G pattern in CDEI again suggesting interactions between both DNA/protein complexes (23) . Thus the data presented here reinforce the model that the CDEI/Cpfl complex interacts with other centromere components (DNA and protein) in the CEN complex.
The halfsites of the CDEI palindromic sequence CACGTG are recognized asymmetrically by Cpfl protein in vitro and in vivo Symmetrical mutations in either half site of the CDEI palindrome CACGTG qualitatively behave almost identical in vitro and in vivo: for example CDEI(5-G) has a lower centromere activity compared to its symmetrical CDEI(6-C) and in vitro has a lower affinity to Cpfl protein in comparison to CDEI(6-C). The imbalance of the contribution of both half-sites to in vivo CEN function and in vitro Cpfl binding is much stronger in vivo, where the difference can be as much as sevenfold, while in vitro the differences are often about 1.5 fold only. Interestingly Cpfl protein produced in E.coli yields a very similar wt-CDEI binding pattern when compared to Cpfl from yeast (24) . But when binding of bacterially produced Cpfl protein to mutant CDEIs was studied the apparent asymmetry was no longer found, while the relevance of the core sequence CACGTG for Cpfl binding was still present (Wilmen and Hegemann, unpubl. data). Additionally, Cpfl produced in E.coli induced the same DNA bend as protein from yeast (34) . These data may indicate that folding and/or modification of Cpfl protein occuring in yeast might contribute to the asymmetry found for Cpfl expressed in yeast.
The in vitro binding studies described here using yeast Cpfl indicate that the non identical sequence requirements for Cpfl binding are an intrinsic property of this DNA/protein complex as such. This asymmetry is enhanced in vivo, which may indicate that the binding specificity of Cpfl protein is in part determined by its ability to interact possibly cooperatively with other centromere components. Such cooperative interactions have been described for the yeast homeodomain protein a2 and its interacting partner GRM1 (39) . It has been estimated that Grml protein raises the affinity of a2 for the operator sequence in the promoter region of a-specific genes by about 50-fold. Similarily the interactions between the CDEI/Cpfl complex and other centromere components discussed here might modify and thus strengthen the binding of CDEI to Cpfl.
The natural CDEI elements found in yeast are not maximized for high affinity Cpfl binding Extension of the 6 bp long palindromic sequence CACGTG of CEN6-CDEI to 10, 12 and 20 bps yields high affinity binding to Cpfl, which is 2 to 4 fold better than wt CEN6-CDEI. Four out of the five palindromic CDEI mutants , which carry an A:T base pair at position 9 showed a reduced level of in vivo mitotic CEN activity. In contrast our control construct, a 10 bp long palindrome without the A:T bp at position 9 [CDEI(2-G)] showed a reduced level of protein binding and reduced in vivo centromere activity (Fig. 4) . Therefore it seems that for maximized in vitro binding the A:T bp at position 9 is important. Inspection of the 16 natural CDEI sequences reveals that 6 of them (CEN5, 6, 7, 10, 12, 14) carry the 6 bp palindrome CACGTG, CEN15 carries a 8 bp and CEN9 carries a 10 bp long palindrome. The other 7 CDEI elements (CEN1,2,3,4,8,11,13,16 ) exhibit interrupted palindromic structures from the type CACRTG with an A:T base pair at position 9 (with the exception of CEN4). Thus this A:T bp might compensate for the negative effect of a nonpalindromic core sequence. Filter binding studies performed with CDEI sequences from 8 different centromere DNAs had already pointed to a specific interaction with Cpfl protein (11) . Here we show that binding of Cpfl to 4 different wild-type CDEI elements with palindromic [CEN6-CDEI (and CEN14-CDEI, data not shown)] and nonpalindromic (CEN2-CDEI and CEN3-CDEI) core sequences results in identical affinities to Cpfl protein. The two centromere DNAs CEN2 and CEN6 also showed identical mitotic CEN activities (Fig. 5 ). This may indicate that the different centromeres carry Cpfl binding sites with very similar binding affinities. High affinity binding like that observed for some of our mutant CDEI elements might not be needed for centromere function or even be disadvantageous for certain aspects (e.g. CEN assembly, meiotic CEN function, CEN DNA replication). It has been shown in several prokaryotic systems that the affinities of specific DNA binding proteins for their binding sites are not maximal, e.g. purified lambda repressor protein mutants bind operator DNA 3 to 600 fold more strongly than wt repressor (40, 41) and symmetrical lac operator mutants are bound by the lac repressor with 8 to 10 fold higher affinity than natural operator sequences (42) .
Palindromic high affinity binding sites have also been identified for another member of the HLH family of DNA-binding proteins, c-Myc which also binds to sites which centrally carry the C-ACGTG motif (4). The optimal binding site was identified in vitro as a 12 base pair long palindrome GACCACGTGGTC but it is unclear if this site is bound by c-Myc in vivo (43) . C-Myc protein as well as the HLH protein Max (both as homodimers) and Myc-Max heterodimers recognize sequences carrying the core element CACGTG (33) . Recently it could be shown that these different homo and heterodimers possess subtly distinct DNA binding specificities, thus possibly directing these proteins to specific subsets of CACGTG-containing promoters in vivo (44) .
The data obtained for CDEI/Cpfl could also be relevant for CDEI analogous sequences found in various yeast promoters. The sequence variability in those sequences is much higher and it is possible that these variations represent a regulatory network to direct Cpfl protein and its putative HLH partners to these sites via a gradual level of sequence specificity.
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